CYTOKINE MARKET ANALYSIS

Market Challenges And Opportunities

Global Cytokine Market Drivers:

Increase in burden of cancer around the world is expected to augment the growth of the global cytokine market over the forecast period. Cytokine-based immunotherapy is a promising field in the cancer treatment, since cytokines are able to modulate the host immune response toward cancer cell, as well as induce tumor cell death. According to the World Health Organization (WHO), Cancer was the leading cause of death across the globe, accounting for more than ten million deaths in 2020, or nearly one in six deaths.

Rising number of diagnostic, therapeutic, & prophylactic applications of cytokines is expected to propel the growth of the global cytokine market during the forecast period. For instance, in November 2021, Synthekine Inc. and Merck entered into a worldwide research collaboration and license agreement to discover, develop, and commercialize novel cytokine therapeutics. The companies will first look into potential therapies for autoimmune illnesses but can later go into immunology, oncology, and other indications.

Global Cytokine Market Restraints:

High costs of cytokines-based therapies is expected to hamper growth of the global cytokine market. Although cytokines are potentially involved in a wide range of applications such as stem cell therapy, cancer therapy, and diagnostics, the high cost of cytokines-based therapies is expected to hinder growth of the cytokine market. According to the National Institutes of Health’s (NIH) report, nondrug costs for treating CRS (Cytokine Release Syndrome) were US$ 30 000 to 36 000 for the average patient and as high as US$ 56 000 for those with severe CRS.

Lack of specificity is expected to hinder growth of the global cytokine market. For instance, the lack of specificity can prove to be a challenge in some diagnostic cases and is a restraining factor for the growth of cytokine the market.

Global Cytokine Market Opportunities:

Increase in research and development and increase in number of clinical trials is expected to provide significant growth opportunities for players in the cytokine market. For instance, in January 2019, NantKwest Inc. announced the launch of Merkel Cell Carcinoma (MCC) Phase II trial deploying novel triple combination of off-the-shelf Natural Killer haNK Cell Therapy with Superagonist IL-15 Cytokine Therapy and PD-l1 Checkpoint Inhibitor Therapy. haNK, taNK, & t-haNK platforms have been designed to address certain limitations of T-cell therapies including the reduction of risk of serious cytokine storms.

Outbreak of COVID-19 (global pandemic) is expected to offer lucrative growth opportunities for players in the global cytokine market. For instance, in September 2020, National Institutes of Health (NIH) awarded a US$ 3 million grant to Researchers at Sanford Burnham Prebys Medical Discovery Institute to study how SARS-CoV-19 weakens immune system and identify drugs to help infected individuals recover. The main objective of the study is to learn how the coronavirus (COVID-19) inactivates the antiviral cytokine pathways.